Processing

Please wait...

Settings

Settings

Goto Application

1. WO2013158585 - BIOMARKERS FOR MONITORING INTERVENTION THERAPIES FOR DIABETES

Publication Number WO/2013/158585
Publication Date 24.10.2013
International Application No. PCT/US2013/036690
International Filing Date 16.04.2013
IPC
A61K 31/70 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
CPC
G01N 2333/805
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
795Porphyrin- or corrin-ring-containing peptides
805Haemoglobins; Myoglobins
G01N 2400/00
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2400Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
G01N 2800/042
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
04Endocrine or metabolic disorders
042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
G01N 2800/52
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
52Predicting or monitoring the response to treatment; Prognosis
G01N 33/6851
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
6803General methods of protein analysis not limited to specific proteins or families of proteins
6848Methods of protein analysis involving mass spectrometry
6851Methods of protein analysis involving laser desorption ionisation mass spectrometry
G01N 33/6893
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
6893related to diseases not provided for elsewhere
Applicants
  • MERCK SHARP & DOHME CORP. [US]/[US]
  • EZOSE SCIENCES INC. [US]/[US]
  • MEHMET, Huseyin [GB]/[US] (US)
  • SOUZA, Sandra, C. [US]/[US] (US)
  • ASADA, Hidehisa [JP]/[US] (US)
  • MIURA, Yoshiaki [JP]/[US] (US)
  • NAKAHARA, Taku [JP]/[US] (US)
  • MCCARTHY, Diane [US]/[US] (US)
Inventors
  • MEHMET, Huseyin
  • SOUZA, Sandra, C.
  • ASADA, Hidehisa
  • MIURA, Yoshiaki
  • NAKAHARA, Taku
  • MCCARTHY, Diane
Common Representative
  • MERCK SHARP & DOHME CORP.
Priority Data
61/635,97120.04.2012US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) BIOMARKERS FOR MONITORING INTERVENTION THERAPIES FOR DIABETES
(FR) BIOMARQUEURS PERMETTANT DE SURVEILLER LES THÉRAPIES ANTIDIABÉTIQUES INTERVENTIONNISTES
Abstract
(EN)
The use of N-linked glycosylation pattern of serum proteins as a biomarker for evaluating the efficacy of intervention therapies for diabetes is disclosed. As disclosed herein, changes in the N-linked glycosylation of total plasma proteins precedes and predicts the decrease in glycated hemoglobin (HbA1c) associated with successful treatment of diabetes. Therefore, measuring changes in N-linked glycosylation of total serum plasma proteins over time may be used as a biomarker to evaluate or access the efficacy of an intervention therapy for diabetes.
(FR)
Cette invention concerne l'utilisation du profil de N-glycosylation des protéines sériques à titre de biomarqueur pour évaluer l'efficacité des thérapies antidiabétiques interventionnistes. Comme décrit dans la présente, les variations de la N-glycosylation des protéines plasmatiques totales précèdent et prédisent la baisse de l'hémoglobine glyquée (HbA1c) associée au succès du traitement antidiabétique. Par conséquent, la mesure des variations de la N-glycosylation des protéines plasmatiques totales dans le temps peut être utilisée pour évaluer ou pour accéder à l'efficacité d'une thérapie antidiabétique interventionniste.
Also published as
Latest bibliographic data on file with the International Bureau